Cash-rich Pfizer to pay $11.6 billion for Biohaven in biggest deal since 2016
- Pfizer will pay $11.6 billion to buy migraine pill maker Biohaven Pharmaceutical.
- It is the biggest deal the drugmaker has made since 2016 in order to beef up its portfolio ahead of patent losses for some cancer drugs.
- Flush with about $32 billion in cash after its success with Covid-19 drugs, Pfizer has been looking to add treatments as patents for its top-selling drugs like blood thinner Eliquis near expiration.
Pfizer will pay $11.6 billion to buy migraine pill maker Biohaven Pharmaceutical, marking the biggest deal by the cash-rich drugmaker since 2016 to beef up its portfolio ahead of patent losses for some cancer drugs.
The deal, announced on Tuesday, will give Pfizer access to Biohaven's approved rimegepant, a potential blockbuster that belong to a class of migraine treatments known as calcitonin gene-related peptide (CGRP) inhibitors.
Flush with about $32 billion in cash on hand after its success with Covid-19 drugs, Pfizer has been looking to add treatments as patents for its top-selling drugs like blood thinner Eliquis near expiration.
The company also expects sales of its Covid-19 vaccines to drop from last year's highs.
"Investors will like this deal. Given Pfizer's strong balance sheet, this is still a small acquisition and we would expect more such deals," Wells Fargo analyst Mohit Bansal said in a note.
The Biohaven deal is the largest since Pfizer's $14 billion purchase of cancer drugmaker Medivation in 2016.
Pfizer will acquire all Biohaven shares that it does not already own for $148.50 per share in cash, a 78.6% premium to the last closing price. It had taken a 2.6% stake in Biohaven in November.
Biohaven shares jumped 70.1% to $141.39 before the bell, while Pfizer was trading flat at $48.60.
With this deal, Pfizer will compete in a crowded market for migraine treatments from other large drugmakers such as Eli Lilly.
Biohaven's rimegepant, sold as Nurtec ODT in the United States, is approved for use as both a treatment and preventative for migraines and is expected to bring in sales of over $4 billion by 2030. It brought in sales of $462.5 million in 2021.
Biohaven is also developing another CGRP inhibitor and testing two non-CGRP drugs in late-stage studies.
After the deal closes, Biohaven shareholders, including Pfizer, will get 0.5 of a share of a new publicly traded company that will retain Biohaven's non-CGRP treatments.